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Short Two sentence summary:  
EEF2K is part of an adaptation pathway that help cells cope with lack of nutrients by regulating 
translation rates. Pharmacological over-activation of the eEF2K pathway with the anti-viral drug 
Nelfinavir rewires this survival stress-adaptation program into a response that is detrimental for 
tumor growth. 
Bullet Points:  
• The anti-viral and anti-tumoral molecule Nelfinavir is a potent eEF2K activator 
• EEF2K activation contributes to NFR-mediated cell death  
• EEF2K deficiency impairs Nelfinavir mediated antitumoral activity  
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Abstract: 
Activation of the elongation factor 2 kinase (eEF2K) leads to the phosphorylation and 
inhibition of the elongation factor eEF2, reducing mRNA translation rates. Emerging 
evidence indicates that regulation of factors involve in protein synthesis may be critical for 
controlling diverse biological processes including cancer progression. Here we show that 
the inhibitors of the HIV aspartyl protease (HIV-PIs), Nelfinavir in particular, trigger a 
robust activation of eEF2K leading to the phosphorylation of eEF2. Beyond its anti-viral 
effects, Nelfinavir has antitumoral activity and promotes cell death. We found that 
Nelfinavir-resistant cells specifically evade eEF2 inhibition. Decreased cell viability induced 
by Nelfinavir was impaired in cells lacking eEF2K. Moreover, Nelfinavir mediated anti-
tumoral activity in vivo was severely compromised in eEF2K-deficient engrafted tumors. 
Our findings imply that exacerbated activation of eEF2K is detrimental for tumor survival 
and describe a mechanism behind the anti-tumoral properties of the HIV-PIs. 
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Introduction:  
Drug repositioning is emerging as a successful strategy that accounts for a significant 
share of newly US Food and Drug Administration (FDA)-approved drugs in recent years [1] [2]. 
The study of unanticipated drugs effects in patients can uncover new pathways and mechanisms 
of biological interest that can contribute to the development of new therapeutics. Early studies in 
HIV patients treated with the HIV aspartyl protease inhibitors (HIV-PIs) have suggested 
interesting off-target actions of these molecules in cancer [3-5].  The HIV-PIs target the viral 
protease and are widely used to treat HIV. In 1997 Nelfinavir (NFR) became one of the first 
HIV-PI to be approved by the FDA for HIV treatment. In addition to its anti-retroviral effects, 
this safe and orally available drug shows promising anti-tumoral activity in mice and humans [6-
10]. Several phase I and phase II clinical trials are investigating the efficacy of NFR 
repositioning in cancer with encouraging initial results [11-15]. NFR has been shown to affect 
multiple pathways regulating cellular homeostasis including the proteasome, the kinase AKT and 
the Unfolded Protein Response (UPR) [16]. Recently we found that NFR is a robust inducer of 
the Integrated Stress Response (ISR), an adaptation response that promotes an ATF4-dependant 
transcriptional program [17]. While some of these pathways may contribute to its anti-tumoral 
activity, none has been demonstrated to be essential and the molecular basis of NFR mediated 
anti-tumoral effects remains unknown [16, 18, 19].  
In this study we generated clonal populations of cells with increased resistance to NFR-
mediated toxicity. These clones showed an unaltered activation of most NFR-mediated 
responses, including those related to the ISR. However, among possible stress and survival 
pathways, we observed the downregulation of the eukaryotic translation elongation factor 2 
kinase (eEF2K), suggesting that it could be a major player driving Nelfinavir cytotoxic effects. 
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Activation of eEF2K is one of the pathways that participate to the restoration of cellular 
homeostasis upon conditions of nutrient or energy depletion by decreasing translation rates at the 
stage of elongation [20-23]. Indeed, the eEF2K activity inhibits the translation elongation factor 
eEF2, which mediates GTP-dependent translocation of the ribosome, thereby promoting peptide 
chain formation. In the tumoral context, increased activation of eEF2K downstream of mTORC1 
inhibition by rapamycin, has been linked to APC-deficient adenoma growth arrest suggesting 
that enhancing eEF2K activity can be beneficial in patients with colorectal cancer [24].  
Here, we report that the anti-cancer molecule NFR triggered a robust eEF2K-dependent 
eEF2 phosphorylation leading to decreased rates of translation elongation.  We found that NFR-
mediated eEF2K activation decreased cell proliferation and promoted cell-death. Consistent with 
these observations, we demonstrated in an in vivo model of engrafted tumors that NFR-mediated 
anti-tumoral activity is eEF2K dependent. Taken together these data indicate that the eEF2K 
pathway can be therapeutically manipulated to drive a response that is detrimental for tumor 
survival.  
Results:  
Nelfinavir resistance correlates with decreased eEF2K expression  
Long-term treatment of immortalized cells with NFR is toxic and triggers cell death [10]. 
To get insight into the mechanisms involved, we treated HeLa cells with 10 µM of NFR and 
selected and characterized clones that survived and proliferated in presence of the drug (Fig 1A). 
NFR concentration can reach up to 17 µM in the plasma of treated patients [25, 26] and around 
10 µM in liver tissues of mice that receive a dose of NFR reproducing the plasma concentration 
measured in patients [17]. Up to these concentrations of NFR we can observe a significant 
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increased viability in the resistant clones compared to the parental population (Fig 1B). We 
compared by RNA sequencing (RNA-seq), parental cells treated with NFR and four clones 
maintained in presence of the drug (Dataset EV1). We observed that many genes involved in 
ribonucleoprotein complex biogenesis and mRNA translation regulation were downregulated in 
the resistant clones compared to NFR treated parental cells.  Among the translation-regulating 
pathways significantly down-regulated in the resistant clones we noticed the decrease of the 
eukaryotic elongation factor 2 kinase (eEF2K) mRNA. This finding was confirmed by real-time 
PCR (Fig 1C) and at the protein level by Western blot (Fig 1D). Then, we interrogated eEF2K 
expression in the clones following NFR withdraw. We found that in two out of three 
representative clones eEF2K downregulation was stable and maintained for more than three 
weeks in absence of NFR (Fig EV1). This indicated that decreased eEF2K expression was not a 
direct consequence of prolonged treatment with NFR, but could be the result of a selective 
advantage in a few cells that bypassed NFR-mediated cell death. This hypothesis implied that 
eEF2K could be engaged by NFR to decrease viability.   
Nelfinavir triggers eEF2K to promote eEF2 phosphorylation  
EEF2K controls the rate of translation elongation through the phosphorylation of the 
eukaryotic elongation factor 2 (eEF2) at threonine 56 (Thr56). We therefore tested whether NFR 
can activate eEF2K by monitoring eEF2 phosphorylation. Short-term treatment with increasing 
concentrations of NFR triggered the phosphorylation of eEF2 in HeLa cells (Fig 2A). As 
expected, eEF2 phosphorylation was absent in eEF2K deficient mouse embryonic fibroblasts 
demonstrating that NFR engages eEF2K to regulate eEF2 (Fig 2B and Fig EV2A). EEF2K 
deficiency did not affect other pathways modulated by NFR [17], including the phosphorylation 
of the translation initiation factor eIF2α or the expression of ATF4 (Fig EV2A). Similarly 
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impairing eIF2α phosphorylation and therefore the Integrated Stress Response (ISR) did not 
affect NFR-mediated eEF2 regulation (Fig EV2B), suggesting that these two pathways are 
engaged independently one from the other. Then, we characterized these responses in the NFR 
resistant clones. NFR was withdrawn from the culture media for a few hours, and the NFR 
response was analyzed at 6 h of treatment. As expected, the clones showed a diminished 
expression of eEF2K protein that correlated with a reduced eEF2 phosphorylation in presence of 
low doses of NFR (Fig 2C  and Fig EV3A). However, other pathways triggered by NFR such as 
the induction of ATF4 (Fig EV3B) were not affected in NFR resistant clones, which even 
expressed high level of NFR-response markers such as CHOP or DNAJB9 (Fig EV3C). 
Investigation of a panel of HIV-PIs used in the clinic as well as hydroxy-t-
butylamidenelfinavir (M8), the active NFR metabolite, showed that most HIV-PIs trigger eEF2 
phosphorylation (Fig 2D). Yet, we consistently found that among the HIV-PIs, NFR is the most 
robust inducer of this pathway at relevant concentrations.  
Nelfinavir does not inhibit the mTORC1 pathway to promote eEF2K activation 
EEF2K activity is regulated by phosphorylation, which occurs at several sites 
downstream of specific signaling pathways. In particular, the mTORC1 downstream p70 S6 
kinase negatively regulates eEFK by promoting its phosphorylation at inhibitory sites thereby 
allowing translation to proceed [20] and AMP-activated protein kinase (AMPK), a sensor of low 
energy status, has been shown to promote activator phosphorylation of eEF2K  [27] (Fig 3A). 
Inhibition of mTORC1 with chemical inhibitors such as rapamycin or the starvation-induced 
activation of AMPK impairs eEF2K phosphorylation leading to its activation and inhibition of 
eEF2 [28, 29]. Because many phosphorylation sites have been shown to regulate eEF2K [30], we 
separated cell extracts on a phos-tag SDS-PAGE to get a comprehensive analysis of its 
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phosphorylation status. No significant changes on the eEF2K phosphorylation pattern were 
detected in presence of NFR while rapamycin or starvation considerably affected the overall 
eEF2K phosphorylation (Fig EV3D). In line with these observations, the dephosphorylation of 
the mTORC1 effectors S6 ribosomal protein or 4EBP1, a hallmark of mTORC1 inhibition and 
treatment with rapamycin, were only minimally affected in presence of NFR (Fig 3B, compare 
lanes 2-4 with 6-7). Importantly this effect was not observed in eEF2K deficient cells  (Fig 3B, 
compare lane 2-4 with lanes 14-16), suggesting that NFR only slightly affects the mTORC1 
pathway downstream of eEF2K activation. Independence from mTORC1 was also confirmed by 
the observation that rapamycin, that does not trigger a strong eEF2 phosphorylation per se, did 
not affect NFR-mediated eEF2 phosphorylation (Fig 3C).  AMPK activation has been shown to 
trigger eEF2K activation both indirectly through mTORC1 inhibition and directly by 
phosphorylating eEF2K [27]. Indeed, the AMPK agonist AICAR is a potent inducer of eEF2K 
dependent eEF2 phosphorylation (Fig 2B and 3B). Interestingly we observed that concentrations 
above 20 µM of NFR triggered AMPK phosphorylation (Fig 3B, lane 3,4 and 15,16) suggesting 
that this pathway could be involved in mediating NFR responses. Yet, deletion of both AMPK 
isoforms α1 and α2 did not affect NFR-induced eEF2 phosphorylation whereas it impaired 
AICAR response (Fig 3D). AKT has been shown to be a target of NFR [10, 31, 32]; we therefore 
monitored AKT phosphorylation. Upon treatment with NFR we did not observe decreased basal 
AKT phosphorylation (Fig 3B). Moreover inhibition of AKT with the selective inhibitor MK-
2206 did not affect NFR-mediated eEF2 phosphorylation (Fig EV3C). Similarly inhibition of 
AKT phosphorylation upon treatment with the Phosphoinositide 3-kinase (PI3K) inhibitors 3-
Methyladenine (3MA) and Wortmanin did not affect NFR-induced eEF2 phosphorylation 
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(Appendix Fig S1). Altogether these data demonstrate that NFR signals eEF2K activation 
independently of the eEF2K activating pathways mTORC1 inhibition, AMPK or the ISR.  
eEF2K activation contributes to decreased translation rates  
To quantify the role of eEF2K in NFR-mediated translation inhibition, we measured 
global translation rates using 35S-labelled methionine incorporation. We found that eEF2K 
deficiency partially rescued NFR mediated decreased translation rates without impacting on 
tunicamycin-mediated regulation of translation (Fig 4A, 4B). In these cells rapamycin triggered a 
relatively weak eEF2 phosphorylation (Fig 2B), thus, eEF2K did not significantly contribute to 
rapamycin-mediated translation decrease (Fig 4B). Similar to eEF2K deficiency, impairing 
eIF2α phosphorylation partially restored methionine incorporation, indicating that both pathways 
contribute to NFR-mediated reprograming of mRNA translation (Fig 4B).  We also examined the 
role of eEF2K in NFR mediated mRNA translation control by measuring polysomal distribution. 
Treatment with NFR resulted in a decrease of mRNA associated to polysomes and an increase of 
free ribosomes, overall reflecting a decrease of protein synthesis, whereas eEF2K deficiency 
reversed this effect (Fig 4C). On the contrary, treatment with the ER-stress inducer tunicamycin, 
triggered a decrease of the polysomal fraction that was unaffected by eEF2K deficiency but was 
rescued in presence of the ISR inhibitor ISRIB or in cells unable to phosphorylate eIF2α (Fig 
EV4A , EV4B). Inhibiting the ISR did not significantly affect the NFR-mediated decrease in 
polysomes (Fig EV4A , EV4B). Interestingly while NFR clearly affected the polysomal profile 
in an eEF2K dependent manner, we did not observe the expected increase of the polysomal 
fraction that is predicted to accumulate upon elongation defects as observed in presence of 
cycloheximide, a molecule that exerts its effect by interfering with the translocation step in 
protein synthesis (Fig EV4C). Instead we observed a decreased polysomal fraction and increased 
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free ribosomes signal. This indicates that specific eEF2K activation and eEF2 phosphorylation 
may affect additional steps in the translation program beyond its function during elongation. 
Previous report have suggested that eEF2 could be involved in the splitting of the 80S ribosomes 
into subunits, a process required for the initiation steps of translation [33].  
The observation that eEF2K deficiency restored the polysomal fraction clearly underlined 
the key role of this pathway in regulating translation by NFR. However this observation is in 
apparent contradiction with the fact that eEF2K only partially restored overall protein synthesis 
(Fig 4A, 4B). A similar observation was made upon treatment with rapamycin (Fig 4B, EV4C). 
It is therefore possible that concomitant regulation of both the initiation and elongation 
machineries may mask the contribution of each mechanism on the polysomal traces. We 
therefore tested eEF2K contribution to elongation by examining NFR regulation of the ribosome 
half-transit time [34]. This was performed by measuring the kinetics of radioactive amino acid 
incorporation into total protein in post-mitochondrial supernatant (PMS) and into completed 
polypeptides released from the ribosome in post-ribosomal supernatant (PRS). The average half-
transit time was determined from the displacement in time between the two lines corresponding 
to the PMS and PRS data plotted as a function of time (Fig. 4D). We measured that NFR 
significantly increased the ribosome half-transit time. This effect on elongation was not observed 
in eEF2K deficient cells indicating that eEF2K negatively regulate polypeptide elongation rates 
in presence of NFR.  
Overall these experiments define eEF2K activation as a key pathway of NFR-mediated 
protein synthesis regulation and indicate that eEF2K beyond it function as a regulator of 
elongation, can affect polysomes by a mechanism that is yet to be identified. 
eEF2K activation decreases proliferation and promotes cell death  
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The observation that loss of eEF2K may confer a fitness advantage to the cells in 
presence of NFR (Fig 1B) prompted us to interrogate whether sustained eEF2K activation could 
affects cell growth and contribute to NFR-mediated cell death. To test this hypothesis we 
measured cell viability and proliferation in NFR treated eEF2K deficient MEFs and control cells. 
Consistently we found that NFR-mediated decreased proliferation was affected by eEF2K 
deficiency in presence of 10 µM NFR (Fig 5A). We performed genome editing by means of 
CRISPR/Cas9 to inactivate the eEF2K gene in additional cell lines (Appendix Fig S2A-C). Loss 
of eEF2K affected NFR-mediated growth inhibition in all populations tested including those 
isolated from HeLa (Appendix Fig S2D), A549 (Appendix Fig S2E) and MCF7 cells (Fig 
Appendix Fig S2F). Moreover reconstitution of eEF2K -/- MEFs with a construct expressing the 
kinase (Appendix Fig S2G), restored NFR responses to the levels observed in wild-type cells 
(Fig 5A). We also monitored eEF2K role in mediating NFR toxicity by analyzing cell viability 
by MTS assay upon increasing doses of NFR. We found that eEF2K deficiency decreased 
sensitivity to NFR (Fig 5B). This was mostly striking at physiological concentrations below 20 
µM. As reported for the growth defect, reconstitution with eEF2K restored full NFR toxicity (Fig 
5C). Similar findings were found in the eEF2K-deficient cell lines tested (Fig 5D, E, and F). 
Next we interrogated NFR-mediated cell death by quantifying dying cells using annexin V and 
propidium iodide (PI) staining after 24h of treatment. In line with the results obtained by 
monitoring NFR sensitivity, we found that eEF2K deficiency decreased NFR-mediated cell death 
and that reconstitution of eEF2K deficient cells with eEF2K restored the response to NFR (Fig 
5G and Appendix Fig S3)  
EEF2K deficiency did not confer a promiscuous resistance to cell death as demonstrated 
by unaltered loss of viability in presence of other compounds such as tunicamycin (TM) or the 
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apoptosis-inducing drug staurosporine (Appendix Fig S4). Other pathways including those 
related to the ISR are activated by NFR and could affect cell viability [7, 10, 17, 35]. Cells 
deficient in key signaling components of the UPR pathway including PERK, ATF4, IRE1, XBP1 
and cells unable to phosphorylate eIF2α were tested for NFR-sensitivity. Compared to control 
cells, no alteration in cell death was observed in these deficiencies (Fig EV5). All together these 
observations demonstrate that sustained activation of eEF2K affects cell viability and contributes 
to cell death and growth inhibition in presence of NFR, in particular at physiologically relevant 
concentrations of the drug; below 20 µM.  
Pharmacological over-activation of eEF2K reduces tumor growth  
To determine the relevance of eEF2K in mediating NFR therapeutic effects in vivo, 
RasV12-transformed proficient or eEF2K deficient MEFs were generated to transplant tumors 
into AGR129 (IFN-α/β, IFN-γ receptor and RAG-2 deficient) mice [36]. Transformation did not 
significantly affect eEF2K activation (Appendix Fig S5A) or its role in mediating NFR 
susceptibility (Appendix Fig S5B). Mice were injected subcutaneously with eEF2K deficient 
cells on one flank and eEF2K proficient cells on the other flank. As reported previously in nu/nu 
immunocompromised mice [37], eEF2K deficiency did not affect overall tumor formation and 
growth in feed animals (Fig 6A). At day 6 post-implantation, a daily treatment with NFR was 
started.  This resulted in growth inhibition of WT tumor, but strikingly did not affect the growth 
of eEF2K deficient tumors (Fig 6A). As expected, NFR treatment increased eEF2 
phosphorylation in post-mortem tumor biopsies (Fig 6B and C), indicating that sustained eEF2K 
mediated eEF2 inhibition is a key factor contributing to the anti cancer properties of NFR in 
vivo.  
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Discussion:  
We have previously shown that NFR triggers a transcriptional program that mostly rely 
on the ISR [17]; however here we found that this pathway is not a main player driving NFR-
mediated toxicity. Indeed, we showed that NFR-resistant clones could survive and proliferate for 
weeks in presence of the drug despite robust and sustained ISR activation. In addition, transgenic 
cells unable to activate ISR are not protected against NFR toxicity. In contrast, we found that 
NFR-mediated toxicity relies on translation reprograming rather than transcriptional responses. 
Mechanistically, this was mediated at least in part by activation of eEF2K, a stress response 
kinase that regulates translation programs. This pathway was downregulated in NFR-resistant 
clones. Moreover, a decreased sensitivity to NFR and an impaired growth inhibition was 
observed in cells with eEF2K deficiency. In mice, we found that the anti-tumoral effects of NFR 
are eEF2K-dependent, demonstrating that overactivation of this pathway within cancer cells can 
affect tumor growth. NFR ability to trigger eEF2K signaling was comparable in all human and 
mouse cell types tested indicating that this pathway is a conserved hallmark of NFR-mediated 
stress response. It is therefore reasonable to predict that this response could be part of the NFR 
anti-tumoral effects observed in cancer patients [10-12].  
The activation of eEF2K is part of an adaptation program that may help stressed cells, 
such as cancer cells, to cope with conditions of low nutriment and energy [38]. This was shown 
for example in eEF2K deficient tumors that were found to be more sensitive to caloric restriction 
[37].   Moreover inhibition of eEF2K suppresses growth of Pten/p53-deficient Triple-negative 
breast cancer (TNBC) with elevated Akt signaling xenografts in vivo [39].  Down-modulation of 
eEF2K in breast cancer cell lines has also been reported to decrease the expression of oncogenes 
such as c-Myc, thereby impacting on survival and growth [23]. These findings clearly indicate 
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that eEF2K activation is a hallmark of stressed cells within tumors. Accordingly, it was proposed 
that an AMPK-eEF2K-dependent reduction of global translation could contribute to preserving 
energy and conferring tolerance to stress in cancer cells [38, 40]. Our observations that increased 
activation of eEF2K may signal cell death and decreased growth could be in apparent 
contradiction with its role as part of an adaptation program. However, deregulated or prolonged 
stress signals can also turn adaptation programs into programed cell death aimed at eliminating 
irremediably damaged cells. This scenario was demonstrated in the context of several stress 
pathways including during ER-stress [41]. It is therefore possible that eEF2K integrates signals 
that promote survival or death depending on the level or duration of its activation status. By 
increasing eEF2K activity, NFR may redirect the eEF2K program toward death. EEF2K 
activation observed in stressed tissues as part of the adaptation program may increase their 
sensitivity to the drug compared to healthy tissues.  The status of eEF2K activation within the 
tumor may therefore influence NFR responsiveness and should be considered as a potential 
biomarker that could indicate NFR as a therapeutic choice. 
The finding that pharmacological eEF2K activation could be detrimental for optimal 
tumor growth is also supported by a study investigating rapamycin effects in a mouse model of 
colon cancer that reported that rapamycin-mediated APC-deficient adenoma growth arrest 
required eEF2K [24]. Rapamycin inhibits the mTORC1 complex, a master regulator that 
integrates the signals from nutrient and energy sensors with cell growth. Expression of many 
mRNA encoding oncogenes or growth promoting factors has been show to be translationally 
regulated downstream of mTOR activity [42]. Interestingly, mTOR can modulate both initiation 
and elongation phase (respectively through 4EBP-1-eIF4E and p70 S6K-eEF2K-eEF2 
downstream effectors) of mRNA translation to facilitate cell proliferation. The discovery that 
 15 
mTOR inhibition is detrimental for tumor development in an eEF2K dependent manner raises 
the possibility that modifying the translational landscape by targeting elongation factors could be 
a promising strategy to decrease tumor growth. Nevertheless, therapeutic approaches aimed at 
targeting mTORC1 relies on a complex network of regulatory loops that affects its function 
impacting on cancer progression but also leading to increase numbers of potential side effects 
[43]. In contrast, NFR does not significantly affect the mTORC1 signaling pathway and 
therefore represents a new valuable tool to study and specifically promote eEF2K activation in 
vitro, in mice as well as in patients.  In this study we show that eEF2K activating pathways such 
as mTORC1 inhibition, AMPK or the ISR were not involved in NFR-mediated eFF2K 
activation. Possible alternative pathway that could contribute to NFR-mediated effects include 
calcium ion influx, hypoxia or ERK signaling that have been proposed to regulate eEF2K [44]. It 
is likely that the identification of NFR cellular targets and mechanism of action will shed new 
light on novel pathways that can drive eEF2K activation. These mechanisms are predicted to be 
complex, and may involve NFR binding to multiple targets [19]. Moreover, despite the fact that 
we do not observe eEF2K activation with the HIV-PIs Amprenavir, we cannot exclude that some 
aspects of the HIV-PIs response could be related to the peptidometic nature of these molecules 
[45]. 
How increased eEF2K activation may affect proliferation and promote death is an 
important question that remains to be solved. It is possible that eEF2K activation may lead to 
exceed the acceptable threshold of overall translation inhibition or may specifically alter the 
repertoire of translated genes by preferentially affecting survival and proliferation factors. 
Malignant cells exhibit altered translational programming that is characterized by augmented 
activity of many components of the translation machinery, leading to increased overall protein 
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synthesis and modulation of specific oncogenic networks [46].  This was shown for example in 
mice engineered to carry only a single copy of the translation initiation factor eIF4E gene [47]. 
These mice develop normally and show a functional translation machinery at basal. However, 
oncogenic transformation and tumorigenesis was affected by decreased eIF4E levels indicating 
that tumors rely on maximal translation capacity [47]. Therefore, therapeutic agents that target 
components of the translation machinery to decrease translation rates hold promise as broad 
activity anticancer drugs that could overcome intra-tumor heterogeneity [48]. NFR, by inhibiting 
eEF2, can decrease global rates of protein synthesis and possibly affect the translation of specific 
mRNAs that could promote tumor cell survival and proliferation. This activity likely contributes 
to the antitumoral effects and decreased cell growth observed upon eEF2K activation.  
In conclusion, the data presented in this study highlight the importance of eEF2K as a 
therapeutic target in cancer and identify NFR, a well-known drug with a relatively safe profile 
and oral bioavailability, as an anti-cancer treatment that over-activates eEF2K to limit tumor 
viability. These data further suggest that in addition of being interesting targets for inhibition, 
stress responses and adaptation programs can be manipulated to provide increased signal that can 
lead to cell death and the elimination of stressed cancer tissues.   
 
Materials and Methods 
Cell culture and Drug Treatment. 
Each knockout or transgenic Mouse Embryonic Fibroblast (MEF) cell line was compared 
to littermate control.  EEF2K WT and KO MEF were provided by A.G. Ryazanov. EIF2αWT 
and eIF2αS51A MEF were from RJ. Kaufman (Sanford Burnham Medical Research Institute, La 
Jolla, CA, USA). MEF IRE1-/-, XBP1-/-, PERK-/- and they respective WT controls were from 
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L. Glimcher (Weill Cornell Medical College, New York, USA). MEF ATF4-/- and ATF4+/+ 
were provided by A. Bruhat (INRA, Saint-Genes-Champanelle, France). AMPKα1α2 WT and 
double KO MEF were from B. Viollet (Institut Cochin, Université Paris Descartes, France). Cell 
lines have not been authenticated and are tested for mycoplasma once per year in the laboratory. 
Nelfinavir Mesylate (CAS 159989-65-8) was from Axon Medchem, LGM pharma; Ritonavir, 
Atazanavir, Lopinavir and Saquinavir were obtained from The NIH AIDS Reagent Program; 
Nelfinavir hydroxy-tert-butylamide (M8) was from Santa-Cruz (sc-208088). Tunicamycin (TM), 
Cycloheximide (CHX), AICAR  (5-amino-1-β-D-ribofuranosyl-imidazole-4-carboxamide), MK-
2206 and Rapamycin were from Enzo-Life Sciences. Doxycycline, Staurosporine, Wortmanin 
and 3-MA were from Sigma-Aldrich. For starvation condition cells were maintained for 1h in 
PBS.  
Immunoblot analysis. 
Every WB shown in the study is representative of at least three independent experiments 
performed in same conditions. Cells and tumor protein extracts were prepared with RIPA buffer 
(50 mM NaCl, 50 mM TRIS pH-7,4, 1 mM EDTA, 0.1% SDS, 1% NP40, 1% Sodium 
Deoxycholate) supplemented with Proteases inhibitors cocktail (Roche), 10 mM Na3VO4, 
50mM NaF, 10mM Na4P2O7 and 5 µM MG132 (Sigma-Aldrich). The following antibodies 
were used for immunoblot analysis: anti-EEF2K (Cell Signaling; #3692); anti-phospho-EEF2T56 
(Cell Signaling; #2331); anti-total-EEF2 (Cell Signaling; #2332); anti-phospho-S6 Ribosomal 
proteinS240/244 (Cell Signaling; #2215); anti-total-S6 Ribosomal protein (Cell Signaling; #2317); 
anti-phospho-AktT308 (Cell Signaling; #9275), anti-total-Akt (Cell Signaling; #9272), anti-
phospho-AMPKαT172 (Cell Signaling; #2535), anti-total-AMPKα (Cell Signaling; #2793S), anti-
4EBP1 (Cell Signaling; #9644); anti-ATF4 (Santa Cruz; sc-200), anti-phospho-eIF2α (Cell 
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Signaling; #3597S), anti-total-eIF2α (Cell Signaling; #9722S); anti-Tubulin (Adipogen; F2C). 
WB quantifications were performed using ImageJ software.  
Polysomal profiling. 
Cells were treated with 20 µM NFR, 10 µg/ml Tunicamycin or DMSO for 6h. Culture 
medium was removed and cells were harvested using cold PBS supplemented with 5 mM EDTA 
and 100 µg/ml Cycloheximide (CHX). After two washes in cold PBS containing 100 µg/ml 
CHX, pellets were resuspended with hypotonic buffer (1.5 mM KCl, 2.5 mM MgCl2, 5 mM Tris 
pH7.4) supplemented with 0.1 µg/ml Heparin, 100 µg/ml CHX, 20 U/ml RNAsin, and proteases 
inhibitors. Equal amount of lysis buffer (Hypotonic buffer 2% DOC, 2% TritonX100, 2.5 mM 
DTT) was added and subsequent cell lysates were vigorously vortexed, incubated 20 minutes on 
ice and centrifuged at 13000 r.p.m. for 10 minutes at 4°C. Post-nuclear lysates were layered on 
10 ml 10–50% (w/v) sucrose gradients (50, 40, 30, 20, 10% sucrose in 80 mM NaCl, 5 mM 
MgCl2, 20 mM Tris pH7.4, 1 mM DTT and 100 µg/ml CHX in DEPC H2O). Gradients were 
centrifuged at 30,000 r.p.m. for 4h at 4 °C and separated through a live OD254 nm ultraviolet 
spectrometer. Comparison of polysomal (P) and subpolysomal (S) abundance was based on the 
measurement of area under the curve. All experiments were repeated at least two times in same 
conditions. P/S ratio were calculated for each condition and normalized to DMSO treated cells.  
Metabolic labeling. 
Cells were treated for indicated times with NFR, 200nM Rapamicin, 1µg/ml 
Cycloheximide or 10 µg/ml TM and incubated for the last 15 minutes with a mixture of L-(35)S-
Methionine/Cysteine (5 µCi/ml). Cells were washed with PBS and lysed with RIPA buffer. 
Samples were analyzed by autoradiography after SDS/PAGE separation or collected on a glass 
fiber filter (GF/C, Whatman). Filters were washed twice with ice-cold 10% TCA, once with 5% 
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TCA, rinsed twice with ethanol, and air-dried before being subjected to liquid scintillation 
counting. Values were normalized as percentage of Mock treated cells. 
Ribosome Half-Transit Time Measurement. 
Ribosome half-transit time measurements were assessed as in [37, 39] with the following 
modifications. 200 000 cells seeded for 24 hrs in 6 well plates were treated for 6 hrs with 20µM 
NFR; after 5.5 hrs treatment medium was replaced with labeling medium (DMEM. With 4500 
mg/L glucose and sodium bicarbonate, without L-methionine, L-cystine and L-glutamine. 
[Sigma-Aldrich] supplemented with 10% FCS, 1% Non Essential Amino Acids (Gibco-Life 
Technologies™) and 2mM L‐Glutamine (AMIMED, Bioconcept)) for 30 minutes before 
addition of 1µCi/well/ml of L-(35)S-Methionine/Cysteine. For Cycloheximide treatment, CHX 
was added at 1µg/ml to the labeling medium for 30 min. For starvation condition, cells were kept 
in PBS for 30 minutes before labeling. At indicated times (5, 7.5, 10, 12.5 and 15 minutes) after 
labeling, cells were washed twice in ice-cold PBS containing 100 µg/ml cycloheximide, and 
lysed by adding 250µl of RSB lysis buffer (10 mM NaCl; 10 mM Tris-HCl, pH 7.4; 15 mM 
MgCl2; 1% Triton X-100 and 100 µg/ml heparin) containing protease inhibitors directly into the 
well. Cell lysate were harvested, vortexed, and incubated on ice for 20 min. Nuclei and 
mitochondria were cleared by centrifugation at 13 000rpm for 10 min at 4°C. 250 µl post-
mitochondrial supernatant (PMS) was mixed with an equal volume of polysomal buffer (25 mM 
Tris-HCl, pH 7.4; 10 mM MgCl2; 25 mM NaCl; 0.05% Triton X-100; 0.14 M sucrose; 500 
µg/ml heparin) and 250 µl was removed to measure incorporation of [35S]-methionine and 
cysteine into total protein (nascent and completed). Polysomes were pelleted by centrifugation of 
the remaining supernatant at 55,000  g for 1 h at 4°C in a Beckman TLA120 rotor. 200 µl post-
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ribosomal supernatant (PRS) was removed to measure the incorporation of [35S]-methionine and 
cysteine into completed proteins. 100 µl of PMS and PRS samples were collected on a glass fiber 
filter (GF/C, Whatman). Filters were washed twice with ice-cold 10% TCA, once with 5% TCA, 
rinsed twice with ethanol, and air-dried before being subjected to liquid scintillation counting. 
Incorporation of [35S]-methionine and cysteine into total protein within the PMS and PRS was 
obtained by linear regression analysis. Ribosome half transit time was calculated using the 
difference of x abscise values chosen for time of 300 sec. 
Cytotoxic assay. 
Cell viability was evaluated by using a 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfonphenyl)-2H-tetrazolium (MTS) assay (Promega, Madison, 
WI). All experiments were done in triplicate and were repeated at least 3 times. The inhibition of 
cell proliferation was expressed as the percentage of vehicle control treated cells. Dose-inhibition 
rate curves were plotted using a five-parameter logistic equation. For all experiments EC50 value 
(the 50% maximal inhibitory concentration) was calculated and mean +/- s.e.m. of at least 3 
independent experiments is shown. 
 
Cell proliferation measurement. 
1,000 cells were seeded in 96 well plates and let adhere for 24h. Just before drug 
addition, cells were counted on a define area of each well using a Spectramax imager technology 
in order to determine the number of cell at time 0. Cells were treated with vehicle or with 10 µM 
NFR and each well was imaged again at indicated times. The fold change of cell number 
compare to time 0 was calculated for each individual well at indicated time. Curves represented 
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the mean +/- s.e.m. of three different wells treated or not with 10 µM NFR. The percentage of 
growth inhibition, was determined using the ratio between growth of treated and untreated cells 
at 72h of NFR treatment. For every cell line, curves showed one representative of 3 experiments 
performed in triplicate in the same conditions and histograms are mean +/- s.e.m. of 3 
independent experiments. 
AnnexinV/PI staining and FACS analysis. 
Annexin V/propidium iodide (PI) staining was performed using eBioscience Kit 
(BMS500FI) according to the manufacturer's guidelines. Briefly, 2x105 cells plated in 12 well 
plates were treated for 24h with 0, 20 or 40 µM NFR. Cells and supernatant were harvested and 
centrifuged 5 minutes at 1200 r.p.m.  Cells were washed in ice-cold PBS and resuspended in 50 
µl of binding buffer containing 2.5 µl of AnnexinV-FITC and incubated for 30 minutes on ice. 
Cells were washed once and resupended in 100 µl of binding buffer containing 10 µl of PI 
(20µg/ml). Flow cytometric analysis was immediately performed using an Accuri flow 
cytometer Instrument (BD Bioscience). 
Mice. 
Animal experiments were approved by the Veterinary Office of the Canton de Vaud and 
the Animal Ethics Committee (authorization 2883). Immuno-compromised AGR 129 (IFN-α/β, 
IFN-γ receptor and RAG-2 deficient) mice were provided by M. Gilliet (Department of 
dermatology, CHUV, Lausanne) and housed at the University of Lausanne in accordance to local 
and national guidelines. 1x106 MEF eEF2K WT-HRasV12 and eEF2K-/- HRasV12 were 
respectively injected subcutaneously into the right and left flank of six to eight-week-old female. 
Tumor growth was followed by measuring size of the tumor with a caliper. Tumor volume was 
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calculated using the formula V=(Lxl2)/2. When tumors reach 200 mm3 mice were randomly 
distributed into two homogenous groups and injected intraperitoneally daily either with vehicle 
(4% DMSO, 5% PEG, 5% Tween 80 in saline) or with 100 mg/kg NFR. Experiments were 
repeated 2 times with 6 to 8 mice per group.  
High-throughput sequencing. 
For RNA sequencing, RNA was extracted using RNeasy mini Kit (QIAGEN) from 3 
independent plates of HeLa cells treated or not with 20 µM NFR and from 4 independent 10 µM 
NFR resistant HeLa cells clones. High-throughput sequencing was performed at the Lausanne 
Genomics Technologies Facility (University of Lausanne) on the Illumina HiSeq 2500 using 
TruSeq SBS Kit v3 reagents. For the RNA-seq analysis, we used a moderated t-test from the R 
bioconductor package "limma" (R version 3.1.1, limma version 3.20.8). The "adjusted p-value", 
correspond to the p-values corrected for multiple testing using the Benjamini-Hochberg method. 
RT-PCR. 
SYBR Green fluorescent reagent and LightCycler480 Real time PCR System (Roche) 
were used for quantitative RT-PCR. Primer sequences used: EEF2K F,5’-
CACCTGGAAGATATTGCCACC-3’; R,5’-GCTTCGCCACGTAGTTGGA-3’; EEF2 F,5’-
AACTTCACGGTAGACCAGATCC-3’; R,5’-TCGTCCTTCCGGGTATCAGTG-3; DNAjB9 
F,5’-TCTTAGGTGTGCCAAAATCGG-3’ ; R,5’-TGTCAGGGTGGTACTTCATGG-3’; CHOP 
F,5’-GGAAACACAGTGGTCATTCCC-3’; F,5’-CTGCTTGAGCCGTTCATTCTC-3’. All RT-
PCR were performed in experimental triplicate and repeated at least 3 times on independent 
samples.  
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Plasmid construction 
LentiCRISPR-v2 for EEF2K targeting: Optimized CRISPR target sequences were cloned 
into the LentiCRISPR-v2 vector (Adgene #52961). The seed sequence was designed in the 
kinase domain of eEF2K as follows: CACCTGGAGCACTACATCGA. A sequence targeting 
luciferase was used as control sgRNA (CTTCGAAATGTCCGTTCGGT). p21-FlagEEF2K for 
EEF2K reconstitution: Human EEF2K was amplified by PCR from pDONR223-EEF2K 
(Addgene #23726) and, sub-cloned into Lentiviral pINDUCER21-plasmid (S. Elledge, Harvard 
Medical School). 
Lentivirus production and cell line infection. 
Lentiviruses were produced as previously described [17]. HeLa, A549 and MCF7 cells 
were infected with lentiCRISPR-v2 viruses targeting Luciferase or EEF2K. Positive populations 
were selected with 2 µg/ml puromycin. Clones were tested by WB for EEF2K protein level. 
MEF EEF2K-/- were infected with p21-FlagEEF2K viruses and GFP positive cells were FACS 
sorted 5 days after infection. Flag-EEF2K expression was induced using doxycycline (1 µg/ml 
for 24h). LZRS-H-rasV12 retroviruses used for MEF EEF2K WT and KO infections were 
provided by K. Lefort (GP Dotto laboratory, UNIL, Lausanne). 
 
Statistical analysis. 
Statistical significance was ascertained by performing appropriate tests described in figure 
legends. Significant differences were indicated by * (p≤0.05), ** (p≤0.01) or *** (p≤0.001).  For 
the RNA-seq analysis, we used a moderated t-test from the R bioconductor package "limma".(R 
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version 3.1.1, limma version 3.20.8). The "adjusted p-value" reported in the Dataset S1, 
correspond to the p-values corrected for multiple testing using the Benjamini-Hochberg method, 
which controls for false discovery rate (FDR).  
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Figure Legends 
Figure 1. Resistance to Nelfinavir triggers eEF2K down-regulation.  
• A Molecular structure of the HIV-PI Nelfinavir (NFR) and schematic representation of 
the protocol used to generate NFR resistant clones. HeLa cells were maintained with 10 
µM NFR. After 15 days, few clones proliferating in the constant presence of 10µM NFR 
in the culture medium were selected and expended for further analysis.  
• B Dose response curves for viability of parental cells (in red) or selected clones (in black) 
upon treatment with NFR for 48h. The green dashed box highlight concentration in the 
physiologically relevant range. Curves are mean ± s.e.m. of 3 independent experiments 
performed in triplicate.  P values were calculated using 2way ANOVA analysis of 
variance between parental cells and each individual clone. Bar graph represents the EC50 
(half maximal effective concentration) of the dose responses. Data are mean ± s.e.m. of 3 
independent experiments performed in triplicate. P values were calculated using 1way 
ANOVA analysis of variance (P value in red) followed by Dunnett’s multiple comparison 
tests. *P value ≤ 0.05, ** P value ≤ 0.01. 
• C The parental population and the NFR resistant clones were analyzed for eEF2K mRNA 
expression by real-time PCR relative to β-actin (mean and s.e.m. from 3 independent 
batches of cells are shown). P values were calculated using 1way ANOVA analysis of 
variance followed by Dunnett’s multiple comparison tests. *P value ≤ 0.05, ** P value ≤ 
0.01, *** P value ≤ 0.001. 
• D The parental population and representative NFR resistant clones were analyzed by WB 
for eFF2K total protein level. Tubulin is used as loading control. Histogram represents 
mean and s.e.m of relative eEF2K level quantified from WB of 4 different batches of 
cells collected at different dates (see also source data). P values were calculated using 
1way ANOVA analysis of variance followed by Dunnett’s multiple comparison tests. *** 
P value ≤ 0.001. 
 
Figure 2. HIV-PIs induces eEF2K dependent eEF2 phosphorylation.   
• A Immunoblot analysis of eEF2 Thr56 phosphorylation (P-eEF2) in HeLa cells treated for 
6h with increasing doses of NFR, and compared with 10 µg/ml tunicamycin (TM), 200 
nM rapamycin (Rapa.) or 1h starvation (Starv.). Tubulin is used as loading control.  
• B eEF2K WT and KO MEF treated for 6h with indicated concentration of NFR, 200 nM 
rapamycin (Rapa.), 1h starvation (Starv.) or 1 mM of the AMPK activator AICAR, were 
analyzed by immunoblot with antibodies directed against total or phosphorylated eEF2 
(Thr56).  
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• C Three representative NFR-resistant HeLa clones were analyzed by Immunoblot for 
eEF2K expression level and eEF2 phosphorylation upon NFR and compared to parental 
HeLa cells. For treatments, medium was replaced for 6h with medium containing DMSO 
(Mock), increasing doses of NFR or 10 µg/ml tunicamycin (TM), or for 1h with PBS for 
starvation (Starv.). Tubulin is used as loading control.  
• D Immunoblot analysis of eEF2 Thr56 phosphorylation in HeLa cells treated for 6h with 
increasing doses of different HIV-PIs as indicated or the NFR metabolite M8 (hydroxy-
tert-butylamide). Molecular structures of the different HIV-PIs used are indicated.  Each 
panel is representative of at least 3 independent experiments. 
Figure 3. NFR-mediated eEF2 phosphorylation is AMPK and mTOR independent.  
• A Schematic representation of signaling pathways targeted by the inhibitors used in this 
study.  
• B eEF2K WT and KO MEF treated for 6h with indicated concentration of NFR, 
Rapamycin (Rapa), AICAR or starved for indicated time in PBS (Starv.), were analyzed 
by immunoblot using indicated antibodies. Tubulin is used as loading control.  
• C A potent mTOR inhibition does not impair NFR-mediated eEF2 phosphorylation. WT 
MEFs were treated with the indicated concentrations of Rapamycin or with vehicle 
(Mock). After 30 minutes, indicated doses of NFR were added and cells were incubated 
for additional 6h and analyzed for phosphorylated S6R and eEF2. Tubulin is used as 
loading control.  
• D NFR-mediated eEF2 phosphorylation is not affected in AMPKα1α2 dKO. 
AMPKα1α2 WT and dKO MEF treated for 6h with indicated concentration of NFR, 
Rapamycin (Rapa), AICAR or starved for 1h in PBS (Starv.), were analyzed by 
immuoblot with indicated antibodies. * anti-total AMPKα antibody give an unspecific 
band with a slightly higher molecular weight in dKO cells. Tubulin is used as loading 
control. Each panel is representative of at least 3 independent experiments 
Figure 4. NFR regulates translation rates by phosphorylating eEF2.  
• A-B EEF2K contributes to the decreased translation observed with NFR without 
impacting translation in presence of TM. A. Quantification of newly synthesized proteins 
at 0, 2, 4 and 6h after 20 µM NFR (left panels) or 10 µg/ml TM (right panels) treatment 
in MEF eEF2K +/+ and eEF2K-/-. Treated cells were labeled for 15 minutes with 35S-
methionine and visualized by SDS PAGE and subsequent autoradiography. 
Autoradiographies from four different experiments (see also source data) were quantified 
and results show percentage of translation compared to untreated cells. The mean and 
s.e.m of four independent metabolic labeling experiments are shown. *P value ≤ 0.05, ** 
P value ≤ 0.01, *** P value ≤ 0.001 obtained using 2way ANOVA analysis of variance 
(in red) followed by Bonferroni posttest (in black). B. eEF2K+/+, eEF2K-/-, eIF2αWT 
and eIF2αS51A MEFs were treated for 6h with indicated doses of NFR, 200 nM 
rapamycin, or 10 µg/ml TM, or for 30 min with 10 µg/ml CHX. 35S-methionine 
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incorporation was measured by liquid scintillation counting. Data are shown as the 
percentage of translation compared to untreated cells. *P value ≤ 0.05, ** P value ≤ 0.01, 
*** P value ≤ 0.001 obtained using 2way ANOVA analysis of variance followed by 
Bonferroni posttest. 
• C Representative polysome profiles of eEF2K WT and KO MEF treated 6h with NFR or 
TM. Area under curve for Sub-polysomes (S) and Polysomes (P) used to calculate the 
P/S ratio were indicated (see also raw data provided). Bar graph represents ratio 
normalized to untreated cells. OD254 nm is optical density at 254 nm. Data showed mean 
±s.e.m. of  P/S ratio calculated from 3 independent experiments. P values were calculated 
using 1way ANOVA analysis of variance followed by Bonferroni posttest; *P value ≤ 
0.05, ** P value ≤ 0.01.  
• D The ribosome half-transit time in MEFs eEF2K+/+ and eEF2K-/- was determined as 
described in Materials and Methods. Incorporation of 35S-Methionine into total protein 
within the PMS and PRS was obtained by linear regression analysis. Presented graphs are 
representative of two (CHX 1 µg/ml for 30 min and Starvation 30 min in PBS in 
eEF2K+/+ cells) to four (NFR 20µM for 6h in eEF2K+/+ and eEF2K-/- cells) 
independent experiments. Indicated values represent the x displacement measurement (in 
time) between the PMS line at 300sec and the PRS line (see also raw data provided). 
Histogram represents mean and s.e.m. of the ribosome half transit time from four 
independent experiments. P values were calculated using two tails unpaired Student's T-
tests; *P value ≤ 0.05. 
 
Figure 5. NFR mediated eEF2K activation impairs cell proliferation and triggers cell death. 
• A  MEF eEF2K WT, KO or KO reconstituted with human eFF2K (FlageEF2K) were 
analyzed for cell growth at indicated times. Fold change (means ± s.e.m of triplicate) of 
the cell number just before treatment are shown.  Histogram shows percentage of growth 
inhibition after 72h of 10 µM NFR.  P values are 1way ANOVA with Bonferroni posttest 
calculated from 3 independent experiments.  *** P value ≤ 0.001.  
• B-F Dose response curves for cell viability after 48h NFR measured using MTS assay. 
Curves and bar graph for EC50 are mean ± s.e.m. of 3 independent experiments 
performed in triplicate. For curves, p values are 2way ANOVA analysis of variance. For 
bar graph, p values are two tails unpaired Student's T-tests (B, E), or 1way ANOVA with 
Bonferroni (C) or Dunnett’s multiple comparison posttests (D and F). *P value ≤ 0.05, ** 
P value ≤ 0.01, *** P value ≤ 0.001. (B,C) eEF2K -/- MEFs show a decrease susceptibly 
to NFR compared to eEF2K +/+ controls (B) whereas eEF2K reconstitution restores NFR 
sensitivity (C).  (D-F), HeLa (D), A549 (E)  and MCF7 (F) clones with CRISPR-Cas9 
generated eEF2K deficiency (CrEEF2K) show a decrease susceptibly to NFR compare to 
control cells (CrLuci).   
• G NFR-mediated toxicity assessed using AnnexinV/PI staining and FACS analysis after 
24h treatment. Histogram shows the percentage of dead cells (AV+/PI+). Data are mean 
 30 
± s.e.m. of 3 independent experiments. P values are 2way ANOVA with Bonferroni 
posttest. *P value ≤ 0.05, ** P value ≤ 0.01, *** P value ≤ 0.001.  
 
Figure 6. eEF2K is required for NFR-mediated antitumoral activity.  
• A Tumor volumes of eEF2K -/- and eEF2K +/+ RasV12 engraft implanted subcutaneously 
in AGR129 mice. Treatment with NFR or vehicle was initiated 6 days post-implantation. 
Data are mean of tumor volume  ± s.e.m. (n = 8 per group). P values were calculated 
using 2way ANOVA followed by Bonferroni posttest comparing WT tumor with vehicle 
or NFR treatment and KO tumors with vehicle or NFR treatment; *P value ≤ 0.05, ** P 
value ≤ 0.01, *** P value ≤ 0.001. Experiment is representative of 2 performed in same 
conditions.  
• B Immunoblots for total and phosphorylated eEF2 of tumor engraftment from (A). (NS, 
Non-Specific signal.) 
• C Bar graph shows relative phosphorylation intensities of eEF2 compared with total 
eEF2 determined by densitometry analysis. Mean ± s.e.m. are shown (n=4). P values 
were calculated using 2way ANOVA followed by Bonferroni posttest ; **P value ≤ 0.01. 
 
 
 
 
 
Expanded View Figure Legends 
 
Figure EV1. eEF2K decreased level in NFR-resistant HeLa clones. 
• NFR was washout from resistant clones culture medium for indicated times and cells 
were harvested and analyzed for eEF2K protein level. Below numbers represent the 
relative eEF2K expression compare to untreated parental cell line and were obtained by 
WB quantification normalizing eEF2K on tubulin levels.  
 
Figure EV2. eEF2K deficiency does not impair NFR mediated ISR induction and vice 
versa. 
• A Activation of the integrated stress response by NFR was not affected by eEF2K 
deficiency. ISR activation was measured in eEF2K -/- MEFs and eEF2K +/+ MEFs by 
immunobloting of the translation factor ATF4 and the phosphorylation of the initiation 
factor eIF2α. NFR response (6h treatment) was compared with treatments using 10 µg/ml 
tunicamycin (TM), an inducer of the integrated stress response, 200 nM rapamycin 
(Rapa.) or 1h of starvation in PBS (Starv.). Tubulin is used as loading control.  
• B NFR mediates eEF2 phosphorylation independently from eIF2α phosphorylation, the 
effector of the ISR. NFR response was analyzed in eIF2α WT MEFs and cells unable to 
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carry eIF2α phosphorylation on Ser51 (eIF2αS51A). Immunoblot analysis was performed 
to assess the phosphorylation of eEF2 and eIF2α as well as ATF4 expression after 6h 
treatment with indicated dose of NFR, 10 µg/ml tunicamycin (TM) and 200 
nM rapamycin (Rapa.) and after 1h of starvation (Starv.).  Tubulin is used as loading 
control. Each panel is representative of at least 3 independent experiments. 
Figure EV3. ISR is not affected in NFR resistant clones and NFR triggers eEF2 
phosphorylation independently of Akt. 
• A Three representative NFR-resistant HeLa clones were analyzed by Immunoblot for 
eEF2 phosphorylation upon NFR and compared to parental HeLa cells (see Fig 2). 
Histogram shows the mean and s.e.m. of p-eEF2/tot-eEF2 ratio obtained from WB 
quantification of three independent experiments. Data were normalized using NFR 40µM 
treated parental cell line as the maximum (100%) p-eEF2 signal for each individual 
experiment. 
• B Immunoblot analysis of NFR mediated activation of ER-stress markers in three NFR-
resistant HeLa clones compared to parental HeLa cells. EIF2α phosphorylation, and 
expression of ATF4 are shown. For treatments, medium was replaced for 6h with 
medium containing increasing doses of NFR or 10 mg/ml tunicamycin (TM), or for 1h 
with PBS for starvation (Starv.) This experiment is representative of 3.  
• C NFR resistant clones and parental HeLa cells were analyzed for expression of the stress 
factors CHOP and DNAjB9 by real-time PCR relative to β-actin (mean and s.e.m. from 3 
independent batches of cells are shown). P values were calculated using 1way ANOVA 
analysis of variance followed by Dunnett’s multiple comparison test; *P value ≤ 0.05, ** 
P value ≤ 0.01, *** P value ≤ 0.001. 
• D eEF2K phosphorylation was measured using phos-tag SDS-PAGE and specific 
antibodies in HeLa cells subjected to indicated treatments. This experiment is 
representative of 3. 
• E MK2206-mediated Akt inhibition does not affect NFR ability to induce eEF2 
phosphorylation. MEFs were treated with indicated concentration of the potent Akt 
inhibitor MK2206 or left untreated. After 30 minutes NFR was added for additional 6h. 
Immunoblot analysis was performed for phosphorylated and total Akt and eEF2 as 
indicated. Panel is representative of 3 independent experiments. Tubulin is used as 
loading control. 
Figure EV4. NFR mediated changes in polysomal profile is not dependent on eIF2α  
phosphorylation. 
• A Representative polysome profiles of WT MEFs treated 6h with NFR or TM with or 
without 500 nM ISRIB. Bar graph represents the ratio of sub-polysomes compared with 
polysomes (P/S). OD254 nm is optical density at 254 nm. Data showed mean ±s.e.m. of  
P/S ratio calculated from 2 independent experiments. P values were calculated using two 
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tails unpaired Student's T-tests comparing ratio +/- ISRIB; *P value ≤ 0.05. ISRIB 
efficiency at inhibiting NFR or TM mediated ATF4 induction was tested by immunoblot. 
 
• B-C Representative polysome profiles of eIF2αWT and eIF2αS51A MEFs treated 6h 
with NFR or TM (B) or WT MEFs treated for 6h with 20 µM NFR or 200 nM Rapamycin 
(C, upper panel) or 30 min with 1 µg/ml CHX (C, lower panel). Data showed mean 
±s.e.m. of  P/S ratio calculated from 2 to 3 independent experiments. P values were 
calculated using 1way ANOVA analysis of variance followed by Bonferroni posttest (B 
and C, upper panel) or two tails unpaired Student's T-tests (C, lower panel); *P value ≤ 
0.05, ** P value ≤ 0.01. 
 
 
Figure EV5. UPR deficiency does not improve viability in presence of NFR. 
Dose response curves for cell viability in MEFs unable to phosphorylate eIF2α 
(eIF2αS51A) or deficient for PERK, ATF4, IRE1, XBP1, and respective control cells 
treated with increasing doses of NFR for 48h. Dose response curves for cell viability. Bar 
graph represents the EC50 (half maximal effective concentration) of the dose responses. 
Data are mean ± s.e.m. of 3 independent experiments performed in triplicate. Statistical 
significance was assessed using 2way ANOVA analysis of variance for dose response 
and two tails unpaired Student's T-tests for EC50. No significant differences were 
measured in the tested cell lines. 
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